- All sections
- C - Chemistry; metallurgy
- C07K - Peptides
- C07K 14/55 - IL-2
Patent holdings for IPC class C07K 14/55
Total number of patents in this class: 1335
10-year publication summary
|
22
|
37
|
50
|
80
|
124
|
136
|
233
|
216
|
201
|
69
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| The Board of Trustees of the Leland Stanford Junior University | 6054 |
44 |
| Cue Biopharma, Inc. | 151 |
41 |
| Cancer Research Technology Limited | 542 |
24 |
| Tusk Therapeutics Ltd | 30 |
24 |
| Amgen Inc. | 3779 |
23 |
| Immunitybio, Inc. | 211 |
23 |
| Delinia, Inc. | 43 |
22 |
| Hoffmann-La Roche Inc. | 3060 |
20 |
| F. Hoffmann-La Roche AG | 7958 |
18 |
| Werewolf Therapeutics, Inc. | 41 |
18 |
| Deka Biosciences, Inc. | 37 |
18 |
| University of Washington | 2157 |
17 |
| GI Innovation, Inc. | 42 |
17 |
| Medicenna Therapeutics Inc. | 35 |
16 |
| Regeneron Pharmaceuticals, Inc. | 3650 |
16 |
| Roche Glycart AG | 144 |
15 |
| Philogen S.p.A. | 120 |
14 |
| Medikine, Inc. | 42 |
14 |
| Alkermes Pharma Ireland Limited | 307 |
13 |
| Synthorx, Inc. | 69 |
13 |
| Other owners | 925 |